Equine Herpesvirus Type 1 (EHV-1) represents one of the most significant viral threats facing the equine industry today. This highly contagious pathogen affects horses worldwide, causing respiratory disease, abortion in pregnant mares, and potentially devastating neurological complications. Understanding the nature, transmission, symptoms, and management of this virus is essential for every horse owner, trainer, veterinarian, and equine facility manager.
What is EHV-1?
EHV-1 is a DNA virus belonging to the Herpesviridae family that specifically targets equines. This virus exists in multiple strains, some more virulent than others, and has the ability to establish latent infections within a horse’s system. Once infected, a horse may harbor the virus for life, even after apparent recovery from active disease. The virus can reactivate during periods of stress, immunosuppression, or when horses are transported or introduced to new environments.
The virus primarily affects three major body systems: the respiratory tract, the reproductive system in pregnant mares, and the central nervous system. The severity and type of disease manifestation depend on multiple factors, including the viral strain, the horse’s immune status, age, vaccination history, and overall health condition.
Transmission and Spread of EHV-1
Direct contact between horses represents the primary transmission route for EHV-1. The virus spreads through respiratory secretions when infected horses cough or sneeze, releasing viral particles into the air and onto surfaces. Horses can transmit the virus during the incubation period before showing clinical signs, making disease control particularly challenging.
Indirect transmission occurs through contaminated equipment, clothing, feed buckets, water troughs, and grooming tools. Farm personnel, veterinarians, and farriers can inadvertently carry the virus on their hands, clothing, or equipment from one horse to another. The virus can survive in the environment for several days under favorable conditions, particularly in cool, moist settings.
Aborted fetuses and placental tissues from infected mares contain extremely high concentrations of the virus and represent a significant source of environmental contamination. Any mare that aborts should be isolated immediately, and all contaminated materials must be handled with strict biosecurity protocols.
Clinical Signs and Symptoms
Respiratory Disease
The respiratory form of EHV-1 infection typically manifests with fever, nasal discharge, coughing, and lethargy. Young horses and those with compromised immune systems are particularly susceptible to respiratory disease. Symptoms usually appear within two to ten days after exposure and may include clear to mucopurulent nasal discharge, decreased appetite, depression, and enlarged lymph nodes under the jaw.
Abortion in Pregnant Mares
EHV-1 abortion typically occurs in the last trimester of pregnancy, most commonly between eight and eleven months of gestation. The abortion often happens suddenly, without warning signs, and the mare usually appears healthy before and after losing the foal. The fetus is typically fresh and well-preserved, which helps distinguish EHV-1 abortion from other causes of pregnancy loss.
Neurological Disease (EHM)
Equine Herpesvirus Myeloencephalopathy (EHM) represents the most feared complication of EHV-1 infection. This neurological form develops when the virus attacks blood vessels supplying the spinal cord and brain, causing inflammation and tissue damage. Clinical signs include weakness and incoordination of the hind limbs, urine dribbling or retention, loss of tail tone, and in severe cases, inability to rise or complete paralysis.
Neurological signs can range from mild ataxia to complete recumbency. Horses may exhibit a characteristic “dog-sitting” position, appearing unable to coordinate their hind limbs properly. The condition can progress rapidly, sometimes within hours, making early recognition and immediate veterinary intervention critical.
Diagnosis of EHV-1
Laboratory confirmation is essential for accurate diagnosis of EHV-1. Veterinarians collect nasal swabs, blood samples, or tissue samples from aborted fetuses for PCR (polymerase chain reaction) testing, which detects viral DNA. Virus isolation and antibody testing may also be performed, though PCR has become the gold standard due to its speed and accuracy.
Clinical assessment combined with laboratory results provides the most reliable diagnosis. Veterinarians consider the horse’s clinical signs, exposure history, vaccination status, and epidemiological factors when evaluating suspected cases. In outbreak situations, multiple horses may be tested to determine the extent of viral spread within a facility.
Treatment and Management
No specific antiviral treatment exists for EHV-1, making supportive care the cornerstone of management. Treatment focuses on maintaining hydration, controlling fever, supporting nutrition, and preventing secondary bacterial infections. Horses with respiratory disease may benefit from anti-inflammatory medications, while those with neurological signs require intensive nursing care.
Neurological cases demand immediate veterinary attention and often require hospitalization. Treatment includes anti-inflammatory drugs to reduce spinal cord swelling, careful nursing to prevent pressure sores in recumbent horses, urinary catheterization if needed, and nutritional support. The prognosis for EHM varies considerably, with some horses making full recoveries while others remain permanently disabled or require euthanasia.
Isolation protocols must be implemented immediately upon suspicion of EHV-1. Infected horses should be separated from the general population, preferably in a dedicated isolation area with separate equipment and personnel. Movement of horses on and off the property should cease until the outbreak is controlled.
Prevention Strategies
Vaccination Programs
Regular vaccination forms the foundation of EHV-1 prevention, though vaccines cannot prevent infection entirely. Current vaccines reduce viral shedding, decrease disease severity, and help prevent abortion in pregnant mares. Pregnant mares should receive vaccinations at five, seven, and nine months of gestation according to manufacturer recommendations.
Performance horses, show horses, and those frequently exposed to new animals benefit from vaccination every three to six months. Young horses beginning their show careers should receive a complete vaccination series followed by regular boosters.
Biosecurity Measures
Strict biosecurity protocols significantly reduce EHV-1 transmission risk. These include isolating new arrivals for at least fourteen days, monitoring temperatures twice daily, maintaining separate equipment for different groups of horses, and requiring hand washing and equipment disinfection between horses.
Limiting horse movement during high-risk periods, such as show season or breeding season, helps reduce exposure opportunities. When attendance at events is necessary, horses should be housed separately from others, avoid nose-to-nose contact, and use dedicated water and feed containers.
Facility Management
Proper stable hygiene includes regular cleaning and disinfection of stalls, equipment, and common areas. Effective disinfectants against EHV-1 include diluted bleach solutions, quaternary ammonium compounds, and other EPA-approved virucidal products. Surfaces should be cleaned of organic matter before disinfectant application for maximum effectiveness.
Ventilation systems should provide adequate air exchange without creating direct drafts between horses. Reducing dust, maintaining appropriate humidity levels, and ensuring good air quality all contribute to respiratory health and may reduce disease transmission.
Outbreak Management
When EHV-1 outbreaks occur, immediate action is critical. Facilities should implement a complete quarantine, cease all horse movement, separate exposed horses from unexposed ones, and monitor temperatures twice daily on all animals. Any horse developing fever should be isolated immediately and tested for EHV-1.
Communication with veterinary authorities, neighboring facilities, and event organizers helps prevent wider disease spread. Many states require reporting of EHV-1 cases, particularly neurological forms, to animal health officials.
Long-Term Implications
Horses recovering from EHV-1 neurological disease may require extended rehabilitation periods. Some horses regain full function within weeks or months, while others experience permanent deficits affecting their athletic careers. Physical therapy, controlled exercise programs, and patience are essential components of successful rehabilitation.
Economic impacts of EHV-1 can be substantial, including veterinary costs, lost breeding opportunities, quarantine expenses, canceled events, and potential long-term care for permanently affected horses. Insurance coverage and emergency funds help facilities weather outbreak-related financial challenges.
Research and Future Developments
Ongoing research efforts focus on developing more effective vaccines, understanding genetic factors that influence disease susceptibility, and identifying treatment options for neurological disease. Scientists continue investigating why certain viral strains cause more severe disease and why some horses develop neurological complications while others do not.
Improved diagnostic tools and better understanding of viral latency patterns may eventually enable more targeted prevention strategies. The equine industry continues advocating for research funding to combat this significant threat to horse health and welfare.
Understanding EHV-1 empowers horse owners and caretakers to implement effective prevention strategies, recognize early warning signs, and respond appropriately when disease strikes. Through vigilant biosecurity, appropriate vaccination, and rapid response to suspected cases, we can minimize the devastating impact of this challenging virus on our equine partners.